Tim Smith

In this episode of Crisis Point, this year’s news regarding benzene found in acne products is discussed by David Light, Neal Bhatia, MD, and Christopher Bunick, MD, PhD.

These data expanded upon limited real-world data on retention of dupilumab past 2 years of treatment for patients with atopic dermatitis.

In this case–control study, investigators identified relevant comorbidities among individuals with bullous pemphigoid before and after their diagnoses.

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

These data resulted from an investigation of the effect of varying image qualities on the diagnostic abilities of a convolutional neural network (CNN) model and clinicians.

The VISIBLE study’s findings indicate that specific strategies may yield more diverse populations in clinical trials for patients with psoriasis and other conditions.

These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.

Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.

These findings highlight the safety and effectiveness of ESO-101 among adult patients with active eosinophilic esophagitis (EoE).

This interview featured a discussion with Browning regarding his team’s findings prior to the FDA approval of tapinarof cream 1% for atopic dermatitis.

The submission of roflumilast’s supplemental New Drug Application to the FDA by Arcutis follows the conclusion of the INTEGUMENT-PED and INTEGUMENT-OLE studies.

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

This interim analysis highlights positive findings from the Measure Up 1 and 2 studies regarding upadacitinib for patients with atopic dermatitis.

These data provide insight into characteristics of those who choose to discontinue systemic therapies for eczema.

This assessment of dupilumab for pediatric and adult patients with moderate-to severe eczema treated for up to 5 years confirms the drug efficacy and safety across age groups.

These long-term results from the ADjoin trial show that long-term lebrikizumab therapy may improve sleep disturbances, pruritus, and skin symptoms, using POEM as an assessment tool.

In this study, investigators described the safety and tolerability of BLV therapy following 48 weeks of therapy among those with CHD.

This analysis involved assessing rates of lifetime as well as prior 12-month treatment use for AUD, in addition to demographic and clinical characteristics linked to AUD treatment.

Investigators looked at the effects of the exposome among patients with atopic dermatitis in order to better understand the influence of such elements as obesity and microorganisms.

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

In this month's episode of Lungcast, Jacob Sands, MD, discusses the American Lung Association’s recently newly-released 2024 State of Lung Cancer report.

This new edition of HCPLive’s monthly newsletter on recent US Food and Drug Administration (FDA) news features highlighted updates from across therapeutic pipelines.

In this analysis, investigators determined that the eliciting dose of an allergen may be an unpredictable marker for the severity of an allergic reaction.

These data highlight some of the most notable findings related to airline travel issues among those with food allergies or with family members with such allergies.

The phase 3 OLYMPIA 1 study highlights the benefits among those with prurigo nodularis of targeting interleukin-31 signaling using nemolizumab.

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis.

In this iteration of the Month in Review series, a list of highlighted stories in the allergy and immunology space covered in the month of November is provided.

The November Month in Review features a set of dermatology news coverage highlights, including FDA news and developments in psoriasis.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.